Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2019 - IJCMAS--ICV 2019: 96.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here

ICV 2019: 96.39
Index Copernicus ICI Journals Master List 2019 - IJCMAS--ICV 2019: 96.39
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2017.6(10): 1379-1385
DOI: https://doi.org/10.20546/ijcmas.2017.610.163


Cefepime/Tazobactam – A Newer and Better β-Lactam/β-Lactamase Inhibitor Combination to Spare Carbapenem Drugs
Kalaivani Ramakrishnan1*, Sameera M. Jahagirdar2, M. Ravishankar2 and Seetha Kunigal1
1Department of Microbiology,
2Department of Anesthesiology, Mahatma Gandhi Medical College and Research Institute, SBV University, Pondicherry-607403, India
*Corresponding author
Abstract:

Gram negative pathogens acts as a significant etiological agent in causing both hospital and community acquired infections for the past few decades. Various resistance mechanisms, especially β-lactamases triggered extensive use of β-lactams. Carbapenems stands as the last resort to save many life threatening diseases. To prevent extensive Carbapenemases dissemination, this study was aimed to know the in vitro susceptibility pattern of Cefepime/tazobactam with carbapenems and other BL/BLI combinations. Between January and December 2015, with 947 non-repetitive Gram negative isolates from various respiratory samples (sputum, broncho-alveolar lavage, pleural fluid, endotracheal aspirates and throat swabs) this prospective study was done in a tertiary care hospital, Puducherry. Isolates were identified and antibiotic susceptibility testing was done with Cefepime/tazobactam and its results were compared with carbapenems and other BL/BLI combinations. Out of 947 isolates, E. coli (44%) was the predominant isolate identified, followed by Klebsiella spp. (27%) and others. The sensitivity pattern of all our Gram negative isolates towards Cefepime/tazobactam ranged from 59% to 100%. Towards carbapenems it ranged between 68%-100% and for other BL/BLI combinations 47%-100% susceptibility was observed. To overcome this emerged β-lactamase enzymes in hospital and community settings, appropriate and adequate antibiotic practices is needed. As there are very few new antibiotics in the pipe-line, antibiotic restriction policy will definitely reserve the high-end antibiotics for the future. We conclude that Cefepime/tazobactam will be a challenging combination almost equal to carbapenems and far better than other BL/BLI combinations in the practice.


Keywords: Cefepime/tazobactam, CPT, BL/BLI, ESBLs, Cefepime.
Download this article as Download

How to cite this article:

Kalaivani Ramakrishnan, Sameera M. Jahagirdar, M. Ravishankar and Seetha Kunigal. 2017. Cefepime/Tazobactam – A Newer and Better β-Lactam/β-Lactamase Inhibitor Combination to Spare Carbapenem Drugs.Int.J.Curr.Microbiol.App.Sci. 6(10): 1379-1385. doi: https://doi.org/10.20546/ijcmas.2017.610.163